StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)

Close on Nov 17, 2026Market cap $26.19MP/E –Yield –

Earnings

Pelthos Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 18, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$15.40M
EPS, Q3 FY2026
-$2.04
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Pelthos Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 18, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open$15.40M–-$2.04Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026before the open$15.60M–-$6.62Release
Q1 FY2026ended Mar 31, 2026May 14, 2026before the open$10.91M–-$3.09Release
Q4 FY2025ended Dec 31, 2025Mar 19, 2026before the open$9.39M–-$6.87Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 18, 2025before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Pelthos Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Pelthos Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Pelthos Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Results
  5. Update
  6. Update
  7. Results
  8. Results
  9. Update
  10. Update
  11. Update
  12. Results
  13. Results
  14. Update
  15. Update

See a number that looks wrong?